Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 23 Dec 2015 |
| Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes | 17 Dec 2015 |
| Novo Nordisk A/S - Share repurchase programme | 14 Dec 2015 |
| Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the US for the treatment of type 1 and 2 diabetes | 9 Dec 2015 |
| Novo Nordisk A/S - Share repurchase programme | 7 Dec 2015 |